Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Ibutilide: A class III rapidly acting antidysrhythmic for atrial fibrillation or atrial flutter
Autore:
Rogers, KC; Wolfe, DA;
Indirizzi:
Univ Mississippi, Med Ctr, Sch Pharm, Dept Clin Pharm Practice, Jackson, MS 39216 USA Univ Mississippi Jackson MS USA 39216 arm Practice, Jackson, MS 39216 USA Univ Mississippi, Med Ctr, Sch Med, Dept Med,Div Cardiol, Jackson, MS 39216 USA Univ Mississippi Jackson MS USA 39216 ,Div Cardiol, Jackson, MS 39216 USA
Titolo Testata:
JOURNAL OF EMERGENCY MEDICINE
fascicolo: 1, volume: 20, anno: 2001,
pagine: 67 - 71
SICI:
0736-4679(200101)20:1<67:IACIRA>2.0.ZU;2-Z
Fonte:
ISI
Lingua:
ENG
Soggetto:
ARRHYTHMIA SUPPRESSION TRIAL; INTRAVENOUS IBUTILIDE; ANTIARRHYTHMIC AGENT; CONVERSION EFFICACY; THERAPY; PROCAINAMIDE; MANAGEMENT; SAFETY; CELLS;
Keywords:
atrial fibrillation; atrial flutter; antidysrhythmic agents;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
25
Recensione:
Indirizzi per estratti:
Indirizzo: Rogers, KC Univ Mississippi, Med Ctr, Sch Pharm, Dept Clin Pharm Practice,Jackson, MS 39216 USA Univ Mississippi Jackson MS USA 39216 e, Jackson, MS 39216 USA
Citazione:
K.C. Rogers e D.A. Wolfe, "Ibutilide: A class III rapidly acting antidysrhythmic for atrial fibrillation or atrial flutter", J EMERG MED, 20(1), 2001, pp. 67-71

Abstract

Ibutilide is an intravenous Class III antidysrhythmic approved for the treatment of recent onset atrial fibrillation or atrial flutter. Pharmacological effect occurs within 30 min, and the efficacy approaches 40%. In contrast to DC electrical cardioversion, which requires anesthesia, pharmacologic cardioversion offers an alternative in which sedation can be avoided. Patients receiving ibutilide should be monitored for at least 4 h after completed drug administration because of a small chance of ventricular dysrhythmia,mainly torsades de pointes. Careful patient selection is the key to avoiding dysrhythmic complications. The purpose of this article Is to review the mechanisms, clinical applications, potential complications, and appropriateuse of ibutilide, (C) 2001 Elsevier Science Inc.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/11/20 alle ore 20:08:29